You are invited to an evening soirée in Soho, New York.
Join the company of like-minded individuals, share your perspective among other trailblazers, enjoy a psychedelic comedy performance, and show your support for the legalization of psychedelic medicine.
Saturday, October 7, 2017
Doors open at 7:00 P.M.
Food served at 7:30 P.M.
Program begins at 8:30 P.M.
$300 (single) | $550 (pair)
MAPS Founder and Executive Director, Rick Doblin, Ph.D., will host an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.
Author Rachel Hope overcame treatment-resistant PTSD after participating in MAPS’ Phase 2 clinical research. Rachel is now a public advocate for the legalization of this potentially life-saving therapy.
Shannon Clare Carlin, M.A., is investigating MDMA-assisted psychotherapy for PTSD as a co-therapist at the Phase 3 study site in Los Angeles, California. Shannon previously treated Phase 2 study participants for anxiety associated with life-threatening illness. Shannon serves as Therapy Training Program Manager, and oversees education for therapists.
Comedian Adam Strauss’ work has been called many things, mostly adjectives. The New York Times said The Mushroom Cure, Adam’s true account of his attempt to treat his severe OCD with psychedelics, “mines a great deal of laughter from disabling pain.” Time Out New York called it “riveting… a true-life tour de force” and named it a Critics’ Pick.
Breakthrough Therapy Designation
Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.
Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.
Together, we can work to heal millions of people suffering from PTSD by supporting groundbreaking research into psychedelic therapies. This research is essential to obtaining government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics. There is a need unmet by modern psychiatry and psychotherapy that psychedelic-assisted therapies can fill.
We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. The first $20,000 donated on-site will be matched 2:1 by generous donors Laura and Ed Littlefield who pledged $40,000.
Special thanks to our hosts, Giancarlo and Stephanie Canavesio, and to host committee members Susan Brody, Sheila Burgel, Sir Ivan, Joshua Mailman and Monica Winsor, John McCormick, Stefanie Frank, Rodrigo Nino, Daniel Pinchbeck, Carey and Claudia Turnbull, Ethan Nadelmann, Ofir Kedar, Tim Hatch, and Ethan Devine. Additional members to be announced.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD.
This event coincides with the Horizons: Perspectives on Psychedelics conference taking place in New York, New York, from October 6-8, 2017.